Our innovative vaccine technology platform - AdVac® - offers hope for accelerated vaccine development. Janssen's AdVac® vectors are based on a specific type of adenovirus. This type of adenovirus has been genetically modified so that it can no longer multiply in humans and cannot cause disease. Because of this they are relatively harmless, and these viruses can be well used to induce desired immune responses in the human body. Want to know more about our AdVac® technology? Watch the video and read more here.
For COVID-19 related press questions, click here.
WHAT IS THE RESPONSE OF JANSSEN TO THE COVID-19 PANDEMIC?
WHAT IMPACT DOES COVID-19 HAVE ON US AS A COMPANY?
Latest press releases
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use